Studies have shown that 55% of prostate tumors have gene fusion (TMPRSS2:ERG) between prostate-specific TMPRSS2 gene and ERG oncogene, and confirmed the existence and expression of TMPRSS2:ERG in PCSC 39. Here, TMPRSS2 is linked to prostate neoplasm.